Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Let’s keep it simple: If you want to delay Alzheimer’s onset, focus on walking and adding nutritious foods, such as walnuts, ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Dementia is a group of diseases that involve having trouble with memory, thinking, reasoning and other brain functions. It is ...

Researchers at the UConn Center on Aging have uncovered causal links between depression and Alzheimer’s disease and related ...

Q. My mother recently died of Alzheimer’s. Her mother had what used to be called “senility,” and Alzheimer’s killed my mother ...

TORONTO -- The antiviral agent valacyclovir demonstrated no benefit in early Alzheimer's disease, the phase II VALAD trial ...

New tests and new treatments are presenting more options for certain patients with Alzheimer's disease. “Today a confluence ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

The nonprofit Alzheimer's Association said Tuesday that some blood tests can be used to diagnose the brain disorder in place ...